Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite
A Phase 1, Open-Label, Single-Dose Study to Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite (ACP-5862)
Sponsor: Acerta Pharma BV
A PHASE1 clinical study on Healthy Subjects and Hepatic Impairment, this trial is completed. The trial is conducted by Acerta Pharma BV and has accumulated 7 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1
-
Oct 2021 — Dec 2022 [monthly]
Completed PHASE1
▶ Show 2 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE1
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE1
First recorded
Nov 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Acerta Pharma BV
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .